2-(4-((10R,14S,18S)-18-(2-amino-2-oxoethyl)-14-(naphthalen-1-ylmethyl)-8,17,20-trioxo-7,16,19-triazaspiro[5.14]icos-11-en-10-yl)phenyl)acetic acid

ID: ALA5074481

PubChem CID: 156599548

Max Phase: Preclinical

Molecular Formula: C38H44N4O6

Molecular Weight: 652.79

Molecule Type: Unknown

This compound is available for customization.

Associated Items:

Bioactivity Summary Target Summary Assay Summary

Names and Identifiers

Canonical SMILES: NC(=O)C[C@@H]1NC(=O)C2(CCCCC2)NC(=O)C[C@@H](c2ccc(CC(=O)O)cc2)/C=C/C[C@@H](Cc2cccc3ccccc23)CNC1=O

Standard InChI: InChI=1S/C38H44N4O6/c39-33(43)23-32-36(47)40-24-26(20-30-12-7-10-28-9-2-3-13-31(28)30)8-6-11-29(27-16-14-25(15-17-27)21-35(45)46)22-34(44)42-38(37(48)41-32)18-4-1-5-19-38/h2-3,6-7,9-17,26,29,32H,1,4-5,8,18-24H2,(H2,39,43)(H,40,47)(H,41,48)(H,42,44)(H,45,46)/b11-6+/t26-,29-,32-/m0/s1

Standard InChI Key: ZYRZDVCTSBJOQD-GZNVFMSSSA-N

Molfile:

 
     RDKit          2D

 48 52  0  0  0  0  0  0  0  0999 V2000
    9.0256   -9.5251    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   12.3900   -3.8396    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
   11.1515   -8.2980    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   10.4289   -5.7758    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    8.3075   -8.2944    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    7.4061   -3.4407    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   14.0215   -7.4663    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   13.1053   -5.0660    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   11.6786   -5.0730    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   14.0130   -9.1296    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   10.5878   -7.0253    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   12.5826   -8.2980    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   11.8692   -7.0597    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    8.1156   -3.8552    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   10.0516   -6.5279    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   10.2561   -5.0799    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    9.7354   -9.1160    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    8.3071   -9.1182    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   10.9632   -4.6693    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   14.3524   -6.6094    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
   13.3043   -7.8765    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   13.5208   -6.6078    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   13.8209   -4.6554    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    9.0203   -7.8795    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   15.2434   -4.6485    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   10.4466   -7.8825    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    6.6943   -3.8580    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   14.5320   -5.0590    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    8.8336   -5.0799    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    6.6971   -4.6738    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    7.5943   -9.5262    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    9.7333   -8.2980    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   14.5360   -5.8818    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
   13.1093   -5.8887    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   14.7350   -8.7156    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    9.5385   -4.6728    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    8.1219   -6.3151    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   11.8692   -7.8825    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    8.1148   -4.6723    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   14.7392   -7.8838    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    8.8358   -5.8977    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   12.3899   -4.6624    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    7.4036   -5.0760    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    7.4032   -5.8997    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   13.3001   -8.7083    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    6.8784   -9.1093    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    6.8815   -8.2809    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    6.1594   -9.5209    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
  6 27  1  0
 24  5  1  0
 37 41  2  0
 29 39  2  0
 21 22  1  0
 17 32  1  0
 32 24  2  0
 35 40  1  0
 18  1  1  0
 42  2  2  0
 23 28  1  0
 43 39  1  0
 15  4  1  0
 19  9  1  0
 12 21  1  0
 34 22  1  0
 39 14  1  0
 16 36  1  1
 26 11  1  0
  5 18  2  0
 36 29  1  0
 16  4  1  0
 26  3  1  0
 18 31  1  0
 41 29  1  0
 27 30  2  0
 26 32  1  1
 10 35  1  0
  9 42  1  0
 14  6  2  0
 21 45  1  0
  8 23  1  6
 16 19  1  0
 42  8  1  0
  8 34  1  0
 11 15  2  0
 22 20  2  0
 44 37  1  0
 38 12  1  0
  1 17  2  0
 43 44  2  0
 28 25  1  0
 28 33  2  0
 45 10  1  0
 38 13  2  0
 40  7  1  0
 30 43  1  0
 21  7  1  0
  3 38  1  0
 31 46  1  0
 46 47  2  0
 46 48  1  0
M  END

Natural Product: No	Oral: No	Chemical Probe: No	Parenteral: No
Molecule Type: Unknown	Topical: No	First In Class: No	Black Box: No
Chirality: No	Availability: No	Prodrug: No

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Unknown

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Calculated Properties

Molecular Weight: 652.79	Molecular Weight (Monoisotopic): 652.3261	AlogP: 4.05	#Rotatable Bonds: 7
Polar Surface Area: 167.69	Molecular Species: ACID	HBA: 5	HBD: 5
#RO5 Violations: 1	HBA (Lipinski): 10	HBD (Lipinski): 6	#RO5 Violations (Lipinski): 2
CX Acidic pKa: 4.20	CX Basic pKa: ┄	CX LogP: 3.76	CX LogD: 0.73
Aromatic Rings: 3	Heavy Atoms: 48	QED Weighted: 0.24	Np Likeness Score: 0.32

References

1. Xiao T, Sun L, Zhang M, Li Z, Haura EB, Schonbrunn E, Ji H.. (2021) Synthesis and structural characterization of a monocarboxylic inhibitor for GRB2 SH2 domain., 51 [PMID:34506932] [10.1016/j.bmcl.2021.128354]
2. Yao, Z J ZJ and 6 more authors. 1999-01-14 Potent inhibition of Grb2 SH2 domain binding by non-phosphate-containing ligands. [PMID:9888830]
3. Ettmayer, P P and 10 more authors. 1999-03-25 Structural and conformational requirements for high-affinity binding to the SH2 domain of Grb2(1). [PMID:10090780]
4. Furet, P P and 5 more authors. 1999-07-01 Structure-based design, synthesis, and X-ray crystallography of a high-affinity antagonist of the Grb2-SH2 domain containing an asparagine mimetic. [PMID:10395476]
5. Gao, Y Y and 8 more authors. 2000-03-09 Inhibition of Grb2 SH2 domain binding by non-phosphate-containing ligands. 2. 4-(2-Malonyl)phenylalanine as a potent phosphotyrosyl mimetic. [PMID:10715157]
6. Lee, Kyeong K, Zhang, Manchao M, Liu, Hongpeng H, Yang, Dajun D and Burke, Terrence R TR. 2003-06-19 Utilization of a beta-aminophosphotyrosyl mimetic in the design and synthesis of macrocyclic Grb2 SH2 domain-binding peptides. [PMID:12801226]
7. Song, Yan-Li YL, Roller, Peter P PP and Long, Ya-Qiu YQ. 2004-06-21 Development of l-3-aminotyrosine suitably protected for the synthesis of a novel nonphosphorylated hexapeptide with low-nanomolar Grb2-SH2 domain-binding affinity. [PMID:15149676]
8. Song, Yan-Li YL and 5 more authors. 2006-03-09 Discovery of a novel nonphosphorylated pentapeptide motif displaying high affinity for Grb2-SH2 domain by the utilization of 3'-substituted tyrosine derivatives. [PMID:16509576]
9. Jiang, Sheng S and 8 more authors. 2009-05-15 Discovery of thioether-bridged cyclic pentapeptides binding to Grb2-SH2 domain with high affinity. [PMID:19362470]

2-(4-((10R,14S,18S)-18-(2-amino-2-oxoethyl)-14-(naphthalen-1-ylmethyl)-8,17,20-trioxo-7,16,19-triazaspiro[5.14]icos-11-en-10-yl)phenyl)acetic acid

Names and Identifiers

Alternative Forms

Associated Targets(Human)

Molecule Features

Drug Indications

Mechanisms of Action

Biocomponents

Calculated Properties

References

Source